medigraphic.com
ISSN 0016-3813 (Print)

2014, Number S2

<< Back Next >>

Gac Med Mex 2014; 150 (S2)

Time from motor symptoms onset to diagnosis of Parkinson’s disease in Mexico

Cervantes AA, Rodríguez VM, Camacho OA, González LP, López RM, Estrada BI, Zúñiga R, Otero CE

Language: Spanish
References: 22
Page: 242-247
PDF size: 226.93 Kb.


ABSTRACT

Introduction: Parkinson’s disease is characterized by a wide spectrum of motor and non-motor symptoms with an insidious onset. Identification of these symptoms by the patient as well as by the physician is determinant in order to achieve an early diagnosis. Objective: To determine the time from motor symptoms onset to the diagnosis of Parkinson’s disease and analyze the clinical and demographic factors related to it. Material and methods: A cross-sectional study was carried out including subjects with Parkinson’s disease seen during the 2011-2012 period and belonging to the Mexican National Parkinson’s Registry. Time from symptom onset to the diagnosis was collected; its relation with demographic and clinical characteristics was assessed. Results: A total of 1,062 subjects were included. Delay in diagnosis was 29.5 months. Predictive factors for a longer diagnostic delay were symptoms onset before 40 years of age (B: –0.350; p ‹ 0.001) and a positive family history of Parkinson’s disease (B: 0.224; p ‹ 0.001). Conclusions: The diagnosis of Parkinson´s disease in Mexico is two and a half times greater than what has been reported for other countries.


REFERENCES

  1. Meissner WG. When does Parkinson’s disease begin? From prodromal disease to motor signs. Rev Neurol. 2012;168(11):809-14.

  2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4.

  3. Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000;57(3):369-72.

  4. Pahwa R, Lyons KE. Early diagnosis of Parkinson’s disease: recommendations from diagnositic clinical guidelines. Am J Manag Care. 2010;16 Suppl Implications:S94-9.

  5. Cervantes-Arriaga A, Rodríguez-Violante M, Zuñiga-Ramírez C, et al. Protocolo de estudio para una cohorte multicéntrica de pacientes mexicanos con enfermedad de Parkinson para evaluar los determinantes motores, no motores y genéticos sobre la progresión. Arch Neurocien (Mex). 2012;17(3):159-64.

  6. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745-52.

  7. Grosset D, Taurah L, Burn DJ, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry. 2007;78(5):465-9.

  8. Murphy R, Tubridy N, Kevenlighan H, O’Riordan S. Parkinson’s disease: how is employment affected? Ir J Med Sci. 2013;182(3):415-9.

  9. Parkinson Study Group. DATATOP: A multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol. 1989;46(10):1052-9.

  10. Martínez-Martín P, Hernández B2, Ricart J; FAST Study Group. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson’s disease. Neurologia. 2014;29(3):153-60.

  11. Femi OL, Ibrahim A, Aliyu S. Clinical profile of parkinsonian disorders in the tropics: Experience at Kano, northwestern Nigeria. J Neurosci Rural Pract. 2012;3(3):237-41.

  12. Saunders-Pullman R, Wang C, Stanley K, Bressman SB. Diagnosis and referral delay in women with Parkinson’s disease. Gend Med. 2011;8(3):209-17.

  13. Breen DP, Evans JR, Farrell K, Brayne C, Barker RA. Determinants of delayed diagnosis in Parkinson’s disease. J Neurol. 2013;260(8):1978-81.

  14. Okubadejo UN, Ojo OO, Oshinaike OO. Clinical profile of Parkinsonism and Parkinson’s disease in Lagos, Southwestern Nigeria. BMC Neurol. 2010;10:1.

  15. Rana AQ, Siddiqui I, Yousuf MS. Challenges in diagnosis of young onset Parkinson’s disease. J Neurol Sci. 2012;323(1-2):113-6.

  16. Crawford P, Zimmerman EE. Differentiation and diagnosis of tremor. Am Fam Physician. 2011;83(6):697-702.

  17. Thacker EL, Ascherio A. Familial aggregation of Parkinson’s disease: a meta-analysis. Mov Disord. 2008;23(8):1174-83.

  18. Farnikova K, Krobot A, Kanovsky P. Musculoskeletal problems as an initial manifestation of Parkinson’s disease: a retrospective study. J Neurol Sci. 2012;319(1-2):102-4.

  19. Wickremaratchi MM, Knipe MD, Sastry BS, et al. The motor phenotype of Parkinson’s disease in relation to age at onset. Mov Disord. 2011; 26(3):457-63.

  20. National Collaborating Centre for Chronic Conditions. Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care. NICE Clinical Guidelines, N.o 35. Londres: Royal College of Physicians; 2006.

  21. Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and pharmacological management of Parkinson’s disease. A national clinical guideline. Edimburgo: Scottish Intercollegiate Guidelines Network (SIGN); 2010.

  22. Centro Nacional de Excelencia Tecnológica en Salud (CENETEC). SSA- 153-08: Diagnóstico y tratamiento de la Enfermedad de Parkinson inicial en el primer nivel de atención. México: Secretaría de Salud; 2008.




2020     |     www.medigraphic.com